Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02457988 · ClinicalTrials.gov registry record · Early Phase 1
The Cirrhosis Outpatient Optimization, Readmission & Safety Study
A Early Phase 1 study, sponsored by University of California, Los Angeles.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 120
- Enrollment target
NCT02457988: Clinical Trial Early Phase 1 study, sponsored by University of California, Los Angeles.
NCT02457988 is a Early Phase 1 study that was terminated before completion, run by University of California, Los Angeles. The registered enrollment target is 120 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (126% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02457988, a Early Phase 1 study, was terminated before completion, sponsored by University of California, Los Angeles.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
A prospective series comparing care incorporating home monitoring and liver care coordination to conventional care for patients with cirrhosis.
Primary Outcome
Compare hospital readmission rates between the intervention group (device) and control group
Interventions
- DEVICE Vivify Kit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-10 |
| Phase | Early Phase 1 |
Why NCT02457988 stopped before completion
NCT02457988 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (126% higher).
The record links to 0 conditions, and to 1 intervention - of which Vivify Kit is the first listed.
NCT02457988 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02457988 about?
NCT02457988 is a clinical study titled "The Cirrhosis Outpatient Optimization, Readmission & Safety Study". A prospective series comparing care incorporating home monitoring and liver care coordination to conventional care for patients with cirrhosis.
What is the current status of trial NCT02457988?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 120 participants. The study started on 2015-04. Estimated completion is 2017-10.
What interventions are being tested in trial NCT02457988?
The interventions under investigation include: Vivify Kit (DEVICE).
Who is sponsoring clinical trial NCT02457988?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02457988's enrollment target sits among peer trials
120 149th of 2000 higher than 1,843 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia